Visiongain Publishes Unfractionated Heparin Market Report 2021-2031
22 February 2021
Visiongain has published a new report on Unfractionated Heparin Market Report 2021-2031: Forecasts By Source (Bovine, and Porcine), By Application (Venous Thromboembolism, Atrial Fibrillation, Renal Impairment, Coronary Artery Disease, and Others), By Route of Administration (Intravenous, and, Subcutaneous), By End User (Hospital, Homecare, Ambulatory Surgical Centers, and Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.
Global Unfractionated Heparin was valued at US$ xx Million in 2020 and is projected to reach at a market value of US$ xx Million by 2031. North America dominated the global Unfractionated Heparin and is projected to witness a CAGR of XX% during the first half of the forecast period i.e. 2021 to 2031.
COVID-19 Impact on Unfractionated Heparin
COVID-19 impact through different recovery models such as V-shaped, U-shaped, W-shaped, and L-shaped; has been taken into consideration while estimating and forecasting the Unfractionated Heparin. Different recovery scenarios are also included in the report for all the segments and regions/nations. The recovery scenarios based on which market has been forecasted and analysed herein the report are mentioned below:
Increasing Prevalence of Cardiovascular Disease
The burden of cardiovascular disease is increasing very rapidly as compared to the last few years and it is expected that cardiovascular disease prevalence will increase during the forecast period. According to the World health organisation approximately 17.9 million people died from cardiovascular disease in 2016. The prevalence of cardiovascular disease is increasing due to increasing high blood pressure, smoking, high cholesterol, diabetes. Increasing cardiovascular disease cases creates a huge demand for the unfractionated heparin treatment. Due to which increasing prevalence of cardiovascular disease is working as a driver for the unfractionated heparin market.
Huge Untapped Potential in Emerging Markets
Governments, international organisations and regulatory authorities in various developing nations are making huge efforts to transition their healthcare infrastructure from less developed and advanced healthcare infrastructure towards a modern, advanced and developed healthcare infrastructure. Increasing focus on healthcare infrastructure is expected to untapped the potential markets in the emerging nations. Emerging markets is expected to be the next most growing market in the forecasted period as the manufactures are already started to take various strategic initiatives such as acquisition & merger, product launch, licence acquisition, regulatory approval and others to dominate or increase their market share in the potential in emerging markets. Moreover, key market manufactures are shifting their focus towards untapped potential in emerging markets which is expected to create more new growth opportunities. Due to this reason the factor is creating various opportunities for the unfractionated heparin market.
Government initiative and awareness program
Various governments, International organizations, regulatory authorities, Independent authority, Non-profit organizations are launching various awareness programs across the developed & developing countries to increase awareness regarding cardiovascular disease. Increasing government initiative and awareness programs for cardiovascular disease is expected to increase demand of unfractionated heparin and is Due to this reason the factor is creating various opportunities for the unfractionated heparin market.
Top companies (GlaxoSmithKline plc, Pfizer, Inc., and Baxter) constitute more than XX% share of the global Unfractionated Heparin. Other companies profiled in the report include: Leo Pharma A/S, Sanofi, Dr. Reddy’s Laboratories Ltd., Aspen Holdings, B. Braun Medical Inc., Fresenius SE & Co. KGaA, Teva Pharmaceutical Industries Ltd. Some of the key developments are listed below:
● In 2019, Meitheal Pharmaceuticals (“Meitheal”), has launched presentations of heparin sodium injection, USP in the United States (US). The company has launched Heparin to decrease the clotting ability of blood and help in prevention of harmful clots from forming in blood vessels. The new presentation is expected to increase company customer base in the market.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Visiongain Publishes Allergy Immunotherapy Market Report 2023-2033
The global Allergy Immunotherapy market is projected to grow at a CAGR of 7.6% by 2033
31 May 2023
Visiongain Publishes AI-based Clinical Trial Solution Providers Market Report 2023-2033
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
26 May 2023
Visiongain Publishes Vaccine Contract Manufacturing Market Report 2023-2033
The global Vaccine Contract Manufacturing Market is projected to grow at a CAGR of 13.2% by 2033
24 May 2023
Visiongain Publishes Cell & Gene Therapy Cold Chain Logistics Market Report 2023-2033
The global Cell & Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15% by 2033